Talphera says current enrollment may support the study and its market research raised the peak sales estimate above $200 million. But enrollment has slowed, the company is seeking FDA feedback on closing early, and quarterly costs rose, so the update does not settle its outlook.
The higher sales estimate comes from market research, not sales already made. Talphera says the enrolled patients may be enough for the study, but enrollment has slowed and the company is still seeking FDA feedback on closing early. The study remains blinded, so no study result or FDA decision is reported.
Follow Talphera, Inc. (TLPH) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TLPH